These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Rheology of sodium hyaluronate saline solutions for ophthalmic use. Calciu-Rusu D; Rothfuss E; Eckelt J; Haase T; Dick HB; Wolf BA Biomacromolecules; 2007 Apr; 8(4):1287-92. PubMed ID: 17355119 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of two chondroitin sulfate ophthalmic solutions in the therapy of spontaneous chronic corneal epithelial defects and ulcerative keratitis associated with bullous keratopathy in dogs. Ledbetter EC; Munger RJ; Ring RD; Scarlett JM Vet Ophthalmol; 2006; 9(2):77-87. PubMed ID: 16497231 [TBL] [Abstract][Full Text] [Related]
27. [A study of the stability of dioxopromethazine in aqueous solutions and ophthalmic instillation]. Capkova Z; Hudecová T; Hatrík S; Havránek E; Vitková Z Ceska Slov Farm; 2004 Jul; 53(4):187-91. PubMed ID: 15369230 [TBL] [Abstract][Full Text] [Related]
28. Topical NSAIDS to control pain in clear corneal cataract extraction. Goguen ER; Roberts CW Insight; 2004; 29(3):10-1. PubMed ID: 15552197 [TBL] [Abstract][Full Text] [Related]
29. Topical estrogen drops for glaucoma? A long way to go. Yin H; Liu X Med Hypotheses; 2008; 70(5):1069. PubMed ID: 18178012 [No Abstract] [Full Text] [Related]
33. The clinical significance of the pH of ophthalmic solutions. FLOYD G; KRONFELD PC; MCDONALD JE J Am Pharm Assoc Am Pharm Assoc; 1953 Jun; 42(6):333-7. PubMed ID: 13069313 [No Abstract] [Full Text] [Related]
34. Reply to Comments by Pescitelli and Bruhn on "Cocaine Hydrochloride Structure in Solution Revealed by Three Chiroptical Methods". Fagan P; Kocourková L; Tatarkovič M; Králík F; Kuchař M; Setnička V; Bouř P Chemphyschem; 2017 Sep; 18(18):2552. PubMed ID: 28834612 [No Abstract] [Full Text] [Related]
35. Reducing Topical Drug Waste in Ophthalmic Surgery: Multisociety Position Paper. Pediatrics; 2023 Apr; 151(4):. PubMed ID: 36970865 [No Abstract] [Full Text] [Related]
36. Notes on the role of hydrogen ion concentration and buffer systems in the preparation of ophthalmic solutions. HIND HW; GOYAN FM; SCHWARZ TW J Am Pharm Assoc Am Pharm Assoc; 1947 Dec; 36(12):413. PubMed ID: 18917442 [No Abstract] [Full Text] [Related]
37. A new concept of the role of hydrogen ion concentration and buffer system in the preparation of ophthalmic solutions. HIND HW; GOYAN FM J Am Pharm Assoc Am Pharm Assoc; 1947 Feb; 36(2):33-41. PubMed ID: 20288772 [No Abstract] [Full Text] [Related]
38. Preparation of ophthalmic solutions with special reference to hydrogen ion concentration and tonicity. MARTIN FN; MIMS JL AMA Arch Ophthalmol; 1950 Oct; 44(4):561-72. PubMed ID: 14770652 [No Abstract] [Full Text] [Related]
39. Dynamic surface activity of biological fluids, ophthalmic solutions and nanostructures. Tonge S; Rebeix V; Young R; Tighe B Adv Exp Med Biol; 2002; 506(Pt A):593-9. PubMed ID: 12613965 [No Abstract] [Full Text] [Related]
40. Serum versus plasma in ophthalmic solutions. Jost KL; Latimer WB Am J Health Syst Pharm; 1996 Aug; 53(16):1964-5. PubMed ID: 8862214 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]